Resource Summary Report

Generated by NIF on Aug 3, 2026

HCC1937

RRID:CVCL_0290
Type: Cell Line

Proper Citation

RRID:CVCL_0290

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0290

Proper Citation: RRID:CVCL_0290

Description: Cell line HCC1937 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: PMID:9699648, PMID:9833771, PMID:9865903, PMID:10635334, PMID:11314036, PMID:12353263, PMID:12419185, PMID:12800145, PMID:14762065, PMID:15162061, PMID:16397213, PMID:16541312, PMID:16959974, PMID:17157791, PMID:17334996, PMID:17932254, PMID:19582160, PMID:19593635, PMID:20070913, PMID:20215515, PMID:21778573, PMID:22032724, PMID:22414580, PMID:22460905, PMID:22585861, PMID:23151021, PMID:23601657, PMID:24094812, PMID:24162158, PMID:24176112, PMID:25485619, PMID:25576301, PMID:25877200, PMID:25892236, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28287265, PMID:28889351, PMID:29273624, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:34339474, PMID:35839778

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1937

Synonyms: Hcc1937, HCC-1937, HCC/1937, Hamon Cancer Center 1937

Cross References: BTO:BTO_0003323, CLO:CLO_0003645, EFO:EFO_0001174, MCCL:MCC:0000180, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2336, BCRJ:0387, BioGRID_ORCS_Cell_line:427, BioSample:SAMN01821555, BioSample:SAMN01821629, BioSample:SAMN03473202, BioSample:SAMN05292445, BioSample:SAMN10987920, cancercelllines:CVCL_0290, CCRID:1101HUM-PUMC000471, CCRID:3101HUMTCHu148, CCRID:5301HUM-KCB09044YJ, Cell_Model_Passport:SIDM00874, ChEMBL-Cells:CHEMBL3308371, ChEMBL-Targets:CHEMBL1075458, CLS:305064, Cosmic:749714, Cosmic:904368, Cosmic:1007153, Cosmic:1046927, Cosmic:1047704, Cosmic:1176626, Cosmic:1235083, Cosmic:1287892, Cosmic:1289389, Cosmic:1309007, Cosmic:1430351, Cosmic:1460235, Cosmic:1472999, Cosmic:1518113, Cosmic:1603207, Cosmic:1995427, Cosmic:2009511, Cosmic:2164992, Cosmic-CLP:749714, DepMap:ACH-000223, DSMZ:ACC-513, DSMZCellDive:ACC-513, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:749714, GEO:GSM155209, GEO:GSM185079, GEO:GSM185080, GEO:GSM186723, GEO:GSM217577, GEO:GSM219873, GEO:GSM274654, GEO:GSM344367, GEO:GSM344417, GEO:GSM350544, GEO:GSM378151, GEO:GSM421867, GEO:GSM459723, GEO:GSM481301, GEO:GSM533403, GEO:GSM533410, GEO:GSM537973, GEO:GSM783936, GEO:GSM783943, GEO:GSM847340, GEO:GSM887045, GEO:GSM888115, GEO:GSM1008900, GEO:GSM1053709, GEO:GSM1172870, GEO:GSM1172961, GEO:GSM1214588, GEO:GSM1238126, GEO:GSM1374506, GEO:GSM1374507, GEO:GSM1401668, GEO:GSM1669851, GEO:GSM2258902, GEO:GSM2258903, GEO:GSM2258904, GEO:GSM2258905, GEO:GSM2258906, GEO:GSM2258907, GEO:GSM2258908, GEO:GSM2258909, GEO:GSM2258910, GEO:GSM2258911, GEO:GSM2258912, GEO:GSM2258913, GEO:GSM2258914, GEO:GSM2258915, GEO:GSM2258916, GEO:GSM2258917, GEO:GSM2258918, GEO:GSM2258919, GEO:GSM2258926, GEO:GSM2258927, GEO:GSM2258928, IARC_TP53:10102, IARC_TP53:10274, IGRhCellID:HCC1937, KCB:KCB 200944YJ, KCLB:9S1937, LiGeA:CCLE_424, LINCS_HMS:50212, LINCS_LDP:LCL-1331, Lonza:905, MetaboLights:MTBLS337, PharmacoDB:HCC1937_485_2019, PRIDE:PXD000309, PRIDE:PXD000394, PRIDE:PXD005295, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0290, PubChem_Cell_line:CVCL_0290, SLKBase:3539, TOKU-E:1402, Wikidata:Q28872477

ID: CVCL_0290

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260802T001246+0000

Ratings and Alerts

No rating or validation information has been found for HCC1937.

No alerts have been found for HCC1937.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 1079 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. Cell reports. Medicine, 6(8), 102252.

Zhang Y, et al. (2025) Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. Cell reports. Medicine, 6(7), 102198.

Han C, et al. (2025) CAMSAP3 Suppresses Breast Cancer Metastasis and Serves as an Independent Prognostic Marker. Technology in cancer research & treatment, 24, 15330338251381866.

Yuan L, et al. (2025) STEAP3 promotes triple-negative breast cancer growth through the FGFR1-mediated activation of PI3K/AKT/mTOR signaling. iScience, 28(6), 112526.

Li H, et al. (2025) Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification. iScience, 28(7), 112860.

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. Cancer research communications, 5(3), 458.

Song L, et al. (2025) Dynamic control of RNA-DNA hybrid formation orchestrates DNA2 activation at stalled forks by RNAPII and DDX39A. Molecular cell, 85(3), 506.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell chemical biology.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Wu R, et al. (2025) Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer. Cancer letters, 627, 217823.

Zhu L, et al. (2025) Synergistic Promotion of Triple-Negative Breast Cancer Tumorigenesis and Metastasis by Oral Polystyrene Nanoplastics Exposure via Alloprevotella-Derived Glutamate and Platelet Activation. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(46), e08310.

Bashtanova U, et al. (2025) The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose. FEBS letters, 599(24), 3618.

Chu Y, et al. (2025) A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. Nature biotechnology.

Komar ZM, et al. (2025) Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. Cancers, 17(13).

Musiani D, et al. (2025) Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. Molecular cell, 85(6), 1072.

Zheng S, et al. (2025) Phosphorylation of plectin by Akt3 promotes triple-negative breast cancer cell invasive migration. iScience, 28(10), 113552.

Shen Y, et al. (2024) Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I. British journal of pharmacology, 181(21), 4262.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(15), 3298.

Zheng SM, et al. (2024) MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer. Cancer research, 84(9), 1460.

Anagho HA, et al. (2024) ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines. Cell reports, 43(7), 114433.